Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,119,406
  • Shares Outstanding, K 43,021
  • Annual Sales, $ 700,970 K
  • Annual Income, $ -99,560 K
  • EBIT $ 99 M
  • EBITDA $ 181 M
  • 60-Month Beta 0.23
  • Price/Sales 1.58
  • Price/Cash Flow 5.96
  • Price/Book 1.59

Options Overview Details

View History
  • Implied Volatility 78.22% (+9.67%)
  • Historical Volatility 28.93%
  • IV Percentile 90%
  • IV Rank 48.52%
  • IV High 119.80% on 10/30/25
  • IV Low 39.03% on 08/20/25
  • Expected Move (DTE 21) 2.48 (9.54%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 8
  • Volume Avg (30-Day) 24
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 1,537
  • Open Int (30-Day) 2,403
  • Expected Range 23.54 to 28.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.59
  • Number of Estimates 3
  • High Estimate 0.64
  • Low Estimate 0.56
  • Prior Year 0.71
  • Growth Rate Est. (year over year) -16.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.00 +13.11%
on 11/25/25
27.16 -4.20%
on 12/16/25
+2.86 (+12.35%)
since 11/24/25
3-Month
19.84 +31.15%
on 10/21/25
27.16 -4.20%
on 12/16/25
-0.03 (-0.12%)
since 09/24/25
52-Week
18.17 +43.20%
on 01/06/25
27.64 -5.86%
on 09/03/25
+6.55 (+33.64%)
since 12/24/24

Most Recent Stories

More News
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care

--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment-- --PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries--...

PCRX : 26.02 (+1.09%)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients,...

PCRX : 26.02 (+1.09%)
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain

-- New data published in Pain Physician shows significant improvement in functional outcomes with iovera° -- -- Fewer iovera° patients required additional spine injections after 180 days -- --  No...

PCRX : 26.02 (+1.09%)
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical

-- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment...

PCRX : 26.02 (+1.09%)
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

BRISBANE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives...

PCRX : 26.02 (+1.09%)
DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business

DOMA Controls 6.8% of Pacira Common Stock

PCRX : 26.02 (+1.09%)
Pacira: Q3 Earnings Snapshot

Pacira: Q3 Earnings Snapshot

PCRX : 26.02 (+1.09%)
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

-- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET --...

PCRX : 26.02 (+1.09%)
Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

-- Milestone advances two-part study evaluating novel, locally administered gene therapy designed to increase anti-inflammatory IL-1Ra production in the knee joint -- BRISBANE, Calif., Nov. 05, 2025...

PCRX : 26.02 (+1.09%)
Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control

-- Advances 5x30 strategy by expanding pipeline with a highly complementary asset that has the potential to provide several days of pain control --  -- Phase 2 program for AMT-143 expected to begin...

PCRX : 26.02 (+1.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug...

See More

Key Turning Points

3rd Resistance Point 26.91
2nd Resistance Point 26.55
1st Resistance Point 26.28
Last Price 26.02
1st Support Level 25.66
2nd Support Level 25.30
3rd Support Level 25.03

See More

52-Week High 27.64
Last Price 26.02
Fibonacci 61.8% 24.02
Fibonacci 50% 22.90
Fibonacci 38.2% 21.79
52-Week Low 18.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar